No quarterly revenue total was found in Rezolute, Inc.'s SEC filings.
Rezolute, Inc. (RZLT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $107.8 million in cash and investments and $934,000 in total debt.
Revenue
—
Net income
$-20.49M
+16.0% vs year-ago quarter
Operating cash flow
$-13.15M
+40.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.20
+24.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
96.72M
+6.5% vs year-ago quarter
Net cash
$106.87M
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RZLT (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1509261
- Former names
- AntriaBio, Inc. (until Dec 7, 2017); FITS MY STYLE INC (until Jan 11, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$21.6M | -$17.4M | -$24.2M | -$19.8M | -$25.9M |
| Net income | -$20.5M | -$16.2M | -$22.8M | -$18.1M | -$24.4M |
| Diluted EPS | -$0.20 | -$0.16 | -$0.22 | -$0.18 | -$0.26 |
| Operating cash flow | -$13.1M | -$13.7M | -$20.3M | -$17.4M | -$22.0M |
| Total assets | $112.8M | $125.5M | $138.6M | $158.7M | $175.5M |
| Total liabilities | $12.2M | $8.6M | $10.6M | $11.5M | $13.4M |
| Stockholders' equity | $100.7M | $116.8M | $128.0M | $147.2M | $162.1M |
| Cash and investments | $107.8M | $120.3M | $132.9M | $152.2M | $167.9M |
| Total debt | $934,000 | $1.1M | $1.3M | $1.5M | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-K | Annual report | Sep 24, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 2, 2026 | Jun 2, 2026 |
All 755 Rezolute, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.